EAM
BBNX

Eventide Asset Management’s Beta Bionics BBNX Stock Holding History

Eventide Asset Management’s Portfolio BBNX Stock Details BBNX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q1 		$59.6M Buy
5,945,488
+950,760
+19% +$14.1M 0.99% 28
2025
Q4 		$152M Buy
4,994,728
+37,476
+0.8% +$1M 2.38% 5
2025
Q3 		$98.5M Buy
4,957,252
+24,901
+0.5% +$438K 1.62% 10
2025
Q2 		$71.8M Buy
4,932,351
+4,332
+0.1% +$61.3K 1.26% 19
2025
Q1 		$60.3M Buy
+4,928,019
New +$91.9M 1.2% 22

Other funds holding BBNX

SCM
Soleus Capital Management Greenwich, Connecticut $2.47B AUM 115.63% 1-Year Est. Return
Morgan Stanley
Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return
SCV
Sands Capital Ventures Arlington, Virginia $421M AUM 26.25% 1-Year Est. Return
FCM
Farallon Capital Management San Francisco, California $17.5B AUM 50.95% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Point72 Asset Management
Point72 Asset Management Stamford, Connecticut $78.1B AUM 55.25% 1-Year Est. Return
VPC
Vestal Point Capital New York $3.58B AUM 189.12% 1-Year Est. Return
RI
RTW Investments New York $10B AUM 135.35% 1-Year Est. Return
VCM
Vanguard Capital Management Malvern, Pennsylvania $4.04T AUM
EP
Eversept Partners New York $1.9B AUM 121.13% 1-Year Est. Return

Eventide Asset Management's BBNX Position: Q1 2026 in Review

Eventide Asset Management increased its Beta Bionics (BBNX) stake by 19% in Q1 2026, buying an estimated $14.1M and bringing the position to 5,945,488 shares worth $59.6M. The position accounts for 0.99% of the portfolio, ranked #28.

Eventide Asset Management first reported a position in BBNX in Q1 2025 and has held it in 5 quarters since. The position peaked at $152M in Q4 2025. 130 funds tracked by Wall St. Rank hold BBNX as of Q1 2026.

  • Eventide Asset Management held 5,945,488 shares of Beta Bionics worth $59.6M as of Q1 2026.
  • Eventide Asset Management bought 950,760 Beta Bionics shares in Q1 2026, an estimated $14.1M.
  • Beta Bionics made up 0.99% of Eventide Asset Management's portfolio in Q1 2026, its #28 holding.
  • Eventide Asset Management first reported a position in Beta Bionics in Q1 2025 and has held it in 5 quarters since.
  • Eventide Asset Management's Beta Bionics position peaked at $152M in Q4 2025.
  • 130 funds tracked by Wall St. Rank held Beta Bionics as of Q1 2026.

Based on Eventide Asset Management's 13F filing for Q1 2026, filed 15 May 2026.